PDE4 inhibitors: a review of current developments (2005 – 2009)

Quinolines as a novel structural class of potent and selective PDE4 inhibitors: Optimisation for oral administration

(2009) Christopher J. Lunniss et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD

(2009) J. Vestbo et al.   EUROPEAN RESPIRATORY JOURNAL

Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors

(2008) J. Nicole Hamblin et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

(2008) M A Giembycz   BRITISH JOURNAL OF PHARMACOLOGY

PDE4 inhibitors: current status

(2008) D Spina   BRITISH JOURNAL OF PHARMACOLOGY

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

(2008) A. B. Gottlieb et al.   CURRENT MEDICAL RESEARCH AND OPINION

Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog

(2008) Gilles Hanton et al.   TOXICOLOGY LETTERS